<DOC>
	<DOC>NCT01626547</DOC>
	<brief_summary>The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.</brief_summary>
	<brief_title>Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology</brief_title>
	<detailed_description>This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study in adult patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anaemia and being treated with Retacrit® to correct haemoglobin levels.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients age ≥18 years . Patients present with chemotherapyinduced symptomatic anaemia. Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia due to their chemotherapy. The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle) Patients eligible for epoetin alfa biosimilar treatment. Patients are not receiving chemotherapy. Patients already included in an epoetin zeta study. Patients presenting with the contraindications to epoetin zeta. Patients presenting with the hypersensitivity to the active substance or any of the excipients. The patient presents erythroblastopenia, or 'pure red cell aplasia' (PRCA). Patients with uncontrolled hypertension. Patients who cannot receive adequate prophylaxis by antithrombotic agents.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>symptomatic anameia</keyword>
</DOC>